BioNTech SE - American Depositary Shares (NQ:BNTX)

97.58 +0.68 (+0.71%)

Delayed Quote Updated: 1:16 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

73 74 Next >

Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support ↗

June 16, 2023

Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v

Via Benzinga

Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories ↗

June 12, 2023

Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger

Via Benzinga

German Woman Sues BioNTech for €150K Claiming Adverse Effects from COVID-19 Vaccine: What You Need to Know ↗

June 12, 2023

BioNTech SE (NASDAQ: BNTX) is reportedly scheduled to appear in court on Monday to defend itself against a lawsuit filed by a German woman seeking damages for alleged side effects of BioNTech's...

Via Benzinga

Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗

June 10, 2023

HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...

Via Talk Markets

The Latest Analyst Ratings for BioNTech ↗

June 01, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

May 29, 2023

Via Benzinga

What To Know About Redburn Partners's Upgrade of BioNTech ↗

May 17, 2023

Via Benzinga

ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer ↗

June 08, 2023

This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors.

Via Benzinga

ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories ↗

June 07, 2023

Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out

Via Benzinga

Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech ↗

June 07, 2023

Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by

Via Benzinga

SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories ↗

June 06, 2023

Benzinga

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

May 15, 2023

Via Benzinga

Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants ↗

June 06, 2023

Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging...

Via Benzinga

3 Ugly Stocks That Actually Hide Beautiful Potential ↗

June 05, 2023

While these underrated stocks with potential has about as much appeal as brown guacamole, they’re actually quite intriguing.

Via InvestorPlace

Why Shares of BioNTech Rose Friday ↗

June 02, 2023

The company released positive trial data for a non-small cell lung cancer therapy.

Via The Motley Fool

BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment ↗

June 02, 2023

BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects.

Via Investor's Business Daily

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

June 02, 2023

From BioNTech SE

Via GlobeNewswire

7 Deeply Undervalued Growth Stocks to Buy in June ↗

June 01, 2023

Investors may see significant rewards betting on these best undervalued growth stocks for June.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

May 26, 2023

Via Benzinga

Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today ↗

May 26, 2023

Benzinga

Via Benzinga

Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases ↗

May 26, 2023

Via Benzinga

Why Pfizer Stock Slipped by 2% Today ↗

May 25, 2023

The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares.

Via The Motley Fool

BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases ↗

May 25, 2023

In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with...

Via Benzinga

As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction ↗

May 24, 2023

(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ: NVDA)...

Via Benzinga

Why Novavax, Pfizer And BioNTech Shares Are Rising Today ↗

May 24, 2023

Shares of vaccine makers Novavax Inc (NASDAQ: NVAX), Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) a

Via Benzinga

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years ↗

May 23, 2023

Both are experiencing a bit of a hangover from declining COVID-19-related sales.

Via The Motley Fool

WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake ↗

May 19, 2023

An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the

Via Benzinga

Palo Alto Networks To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Thursday ↗

May 18, 2023

Needham raised the price target for Dynatrace, Inc. (NYSE: DT) from $52 to $56. Needham analyst James Ricchiuti maintained a Buy rating. Dynatrace shares gained 1.9% to $47.95 in pre-market trading.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2023 ↗

May 17, 2023

Via Benzinga

Why Matinas BioPharma Stock Is Sinking Today ↗

May 11, 2023

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have ended an mRNA-based collaboration.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.